Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin in Subjects With Nephropathy Due to Type 2 Diabetes

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Mar 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2015 Status changed from planning to recruiting, based on a NephroGenex media release.
24 Mar 2015 According to a media release, NephroGenex received support from the EMA on the new endpoint and the study design for their ongoing phase III trial in diabetic nephropathy. The EMA indicated that the current phase III program could support a Marketing Authorization Application for full market approval in Europe.
26 Jun 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com